RxDoctor Payments Data

Kathleen Clifford, NP

Nurse Practitioner · Boise, IDNPI 1750303491

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $83,927 of the $119,185 with a category attached, or 70.4%. 9 manufacturers reported payments, led by Beigene USA, Inc. at 58.7% of the total. Reporting peaked in 2021 at $49,436 and has fallen 98.4% since, to $800 in 2024. Among nurse practitioner clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$119,185in general payments, 2019–2025

Across 207 payments — averaging $575.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene USA, Inc.$70K
  • AstraZeneca$22K
  • Coherus Oncology, Inc.$9K
  • Karyopharm Therapeutics Inc.$6K
  • Sanofi$6K
  • Seagen Inc.$4K
  • plus $3K from 3 others

What the payments were for

  • Consulting fees$5,1654%
  • Speaking & faculty fees$83,92770%
  • Travel & lodging$26,21822%
  • Food & beverage$3,8743%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Beigene USA, Inc.109$70,018
AstraZeneca38$22,299
Coherus Oncology, Inc.21$8,727
Karyopharm Therapeutics Inc.9$5,917
Sanofi11$5,678
Seagen Inc.9$4,037
Johnson & Johnson8$1,309
Pfizer1$900
AbbVie1$300

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$119,185 in reported general payments places this provider in the 95th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$32,811
Medicare patients
281
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$14,167
Ondansetron OdtOndansetron16$797
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$698
Acyclovir13$587
Letrozole18$506
Potassium Chloride23$415
Tamoxifen Citrate19$412
Oxycodone Hcl15$392
Anastrozole20$276
Dexamethasone16$244
Prochlorperazine Maleate13$205
Olanzapine13$196
Gabapentin19$174
Levofloxacin16$77
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$900$14,16720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →